Talentcube Returns to “Die Höhle der Löwen”
Phenom, the global leader in Talent Experience Management (TXM), today announced that Talentcube, the experience-driven video technology startup it acquired in 2021, will return to the popular “Die Höhle der Löwen” (“Lions Den”) show where entrepreneurs pitch their business to potential investors and aspire to attract financing for future growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005624/en/
Carsten Maschmeyer (back center), German business leader and investor, celebrates with Talentcube — a Phenom company — during its return to the “Lions Den.” © Phenom
Debuting on May 16, the new Lions Den segment will revisit the successful investments made in Talentcube and its innovative video technology, culminating with being acquired by Phenom. Talentcube originally appeared on the show in 2017 and quickly won the support of well-known German business leader and investor Carsten Maschmeyer.
"Talentcube's video technology is a perfect example of the kind of groundbreaking technology we invest in to deliver value to people and businesses around the world through startups. The exit to the US unicorn has exceeded our expectations. We are proud to now be involved in Phenom," Maschmeyer stated.
Talentcube’s founders envisioned a future where remote video hiring could be just as authentic and engaging as in-person hiring. As part of Phenom’s Talent Experience Management (TXM) platform for candidates, recruiters, employees and hiring managers, that vision has become a reality — providing seamless video functionality for a post-COVID, hybrid workforce and a differentiator in the increasingly competitive talent acquisition market.
“With skills shortages around the world, companies are looking to hire, develop and retain qualified employees as quickly and accurately as possible. Our video technology can deliver high-value experiences that benefit every talent stakeholder across the entire talent journey,” said Sebastian Hust, Sr. Director, Talent Experience Strategy, Phenom.
Phenom’s video technology helps recruiters and hiring teams qualify candidates faster and with confidence. As part of a holistic talent experience, recruiters can engage with and evaluate candidates beyond written words — all within the Phenom CRM. Video Assessments directly reduces time to hire by alleviating screening bottlenecks while providing a consistent approach to screening organizations’ best-fit candidates.
Recently recognized as a Strategic Leader in Fosway’s 2022 9-GridTM for talent acquisition for the second consecutive year, visit phenom.com to learn why Phenom TXM is dramatically different and how it delivers experience and AI at scale. Visit talentcube.com to learn more about the upcoming segment.
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, AI-Scheduling, Video Assessments, Talent Marketplace, Career Pathing, Employee Resource Groups, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend.
Phenom was ranked among the fastest-growing technology companies in Deloitte Technology's Fast 500 for four years in a row, has been recognized in Business Intelligence Group's 2021 and 2022 Artificial Intelligence Excellence Awards and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom. For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005624/en/
Contact information
Media Contacts:
Jannes Zwirner I jannes.zwirner@tonka-pr.com I +49.172.3650385
Julia Trzinski I julia.trzinski@tonka-pr.com I +49.179.6178513
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom